Navigation Links
Biodel Reports Fourth Quarter and Fiscal Year 2010 Financial Results
Date:12/9/2010

DANBURY, Conn., Dec 9, 2010 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the fourth quarter and fiscal year ended September 30, 2010.

Fourth Quarter and Fiscal Year 2010 Financial Results

Biodel reported a net loss for the quarter ended September 30, 2010 of $8.1 million, or $0.31 per share, compared to a net loss of $10.5 million, or $0.44 per share, for the quarter ended September 30, 2009.

Net loss applicable to common stockholders for the fiscal year ended September 30, 2010 was $38.3 million, or $1.58 per share, compared to $43.3 million, or $1.82 per share, for the fiscal year ended September 30, 2009.

Research and development expenses were $4.5 million for the quarter ended September 30, 2010, compared to $7.9 million for the same period in the prior year.  For the fiscal year ended September 30, 2010, research and development expenses were $26.2 million, compared to $32.3 million for the fiscal year ended September 30, 2009.  The decrease in research and development expenses was primarily due to reductions in clinical, manufacturing, device development and personnel expenses and was partially offset by increases in regulatory expenses associated with the submission of the new drug application (NDA) for Linjeta™.

General and administrative expenses totaled $2.4 million for the quarter ended September 30, 2010, compared to $2.6 million for the same period in the prior year. General and administrative expenses totaled $11.0 million for the year ended September 30, 2010, compared to $11.0 million for the fiscal year ended September 30, 2009.  

Expenses for the fiscal year ended September 30, 2010 and 2009 include $5.6 and $5.1 million in stock-based compensation expense related to options granted to employees and non-employees.

Biodel did not recognize any reve
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
2. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
3. Biodel Awarded $1.2 Million in Therapeutic Discovery Research Grants From IRS
4. FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjetaâ„¢
5. Biodel to Present at Upcoming Conferences
6. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
7. Biodel Appoints Arthur Urciuoli to its Board of Directors
8. Biodel to Raise $9.4 Million Through Registered Direct Offering
9. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
10. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
11. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Showed Significantly Improved Functioning Within Three ... ... Nearly half of patients,with schizophrenia fail to remain on their medication ... from a new international,study showed that patients treated with risperidone long-acting ...
... Phase III Clinical Trial of Acetavance(TM) for the Treatment of ... ... Trial of Omigard(TM) Completes Patient Enrollment, SAN DIEGO, May ... company focused on in-licensing,developing and commercializing proprietary product candidates principally,for ...
Cached Medicine Technology:Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 2Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 3Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 4Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 5Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 6Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 2Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 3Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 4Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 5Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 6Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 7Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 8Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 9
(Date:7/10/2014)... -- Most professional football players who have shoulder stabilization ... new study finds. Shoulder instability is a common ... after surgery to fix the problem has been unclear, ... 60 players who had shoulder stabilization surgery. Ninety percent ... play, defined as playing in at least one regular ...
(Date:7/10/2014)... who have a vasectomy may be at increased risk ... But the risk is comparatively small, the researchers acknowledged. ... more research is needed to determine if the study ... researchers analyzed data from more than 49,400 American men ... During that time, 6,023 cases of prostate cancer were ...
(Date:7/10/2014)... better prepared to respond to an active shooter incident ... study in the journal Prehospital and Disaster Medicine ... the EMS provider comfort level with respect to entering ... neutralized or working with law enforcement personnel during that ... shooting, the Virginia Tech campus shooting, the 2009 Fort ...
(Date:7/10/2014)... health concerns in the United States, with 32 percent ... 2012. As health problems such as childhood obesity grow, ... the problem. , A new study, led by Jenine ... at Washington University in St. Louis, examined the use ... conversations about the issue of overweight kids. , The ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) patients ... of life. Some patients have disturbed sleep/wake patterns ... while other patients may be subject to sudden ... PD patients may exhibit REM-sleep behavior disorder (RBD), ... even before motor symptoms appear. A review in ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2
... is a serious complication that can occur in children ... lead to heart attack, pulmonary embolism and other cardiovascular ... research performed in Italy by the Laboratory of Genetic ... Catholic University in collaboration with the Haematology Division of ...
... Philadelphia have discovered a second gene that causes Alagille ... affects many organs.// , This finding may have ... Children's Hospital team had earlier discovered the first gene ... that mutations in the NOTCH 2 gene were linked ...
... solid food to infants less than six months old is ... food allergies later and new moms should rather breastfeed them ... be avoided for the first six months, and certain items ... introduced until even later, according to the American College of ...
... Danish residents revealed that a specific mutation in the CHEK2 ... cancer in her lifetime. The study, which was the first ... cancer risk associated with it, in the general population, will ... of Clinical Oncology. ,"Our study shows that ...
... compounds in cocoa could improve blood circulation, according ... flow// in menopausal women with high cholesterol.,'The totality ... new insights into how cocoa flavanols may improve ... known,' said Harold Schmitz, PhD, Chief Science Officer ...
... the University of Georgia have suggested that cross-immunity created ... strain protect against infection //,by related serotypes thus leading ... This finding would help understand the pattern of ... since about the mid 1980s, there's been a sequential ...
Cached Medicine News:Health News:Thrombosis, a Serious Risk in Children with Leukemia 2Health News:Second Alagille Syndrome Gene discovered: More information on kidney disease 2Health News:CHEK 2 Gene Mutation Triples Breast Cancer Risk 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 3
Premium Full Color Digital Ultrasound...
... The new ACUSON CV70 cardiovascular ultrasound ... capabilities in a powerful, all-digital ultrasound ... sensitivity, color flow sensitivity and spatial ... the ACUSON family of cardiovascular products. ...
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m...
AngioSpeed V series, it is an Angiography system designed for vascular treatment in various radiological regions, cardiology, and neurology. SHIMADZU brings you a single system with all units fused t...
Medicine Products: